Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Eli Lilly -- Ignore unavailable to you. Want to Upgrade?

To: Bull-like who wrote (445)	12/11/1998 4:02:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 642

Evista Reduces Breast Cancer Incidence In Postmenopausal Women INDIANAPOLIS, IN -- Dec. 11, 1998 -- Eli Lilly and Co.'s osteoporosis drug Evista(R) (raloxifene hydrochloride) appears to reduce the incidence of newly-diagnosed invasive breast cancer, potentially the most serious type of breast cancer, by 63 percent among postmenopausal women taking the therapy for more than three years. Additional three-year findings from the largest of these placebo-controlled studies show that Evista also has significant benefits on vertebral (spinal) fractures and cholesterol levels. The new breast cancer data will be reported tomorrow (Dec. 12) at the 21st San Antonio Breast Cancer Symposium by V. Craig Jordan, Ph.D., director, Lynn Sage Breast Cancer Research Program, Robert Lurie Comprehensive Cancer Center, Northwestern University and chairman of the Evista Oncology Advisory Board. "This is a significant breakthrough in women's health," Jordan said. "Not only is Evista helping a woman prevent bone loss and the development of vertebral fractures after menopause, but it's also continuing to reduce her risk of breast cancer over time. The reductions in breast cancer risk seen to date in these trials are extremely important and provide invaluable information for the additional large-scale testing of Evista in the prevention of breast cancer." These data, an update from those presented earlier this year at the American Society of Clinical Oncology, were gathered from 10,575 postmenopausal women enrolled in 10 randomised, double-blind, placebo-controlled osteoporosis studies. The women, who ranged in age from 31 to 80, were taking daily Evista therapy for a median follow-up of 40 months and a maximum follow-up of 55 months. Overall, there was a 55 percent reduction in risk for all types of breast cancer among postmenopausal women taking Evista. Approximately 7,700 of these women are participating in the six-year Multiple Outcomes of Raloxifene Evaluation (MORE), an ongoing osteoporosis treatment study. The remainder are healthy postmenopausal women enrolled in osteoporosis prevention trials. Women were not enrolled in these trials based on breast cancer risk. Mammograms were routinely performed on an annual or biannual basis in all placebo-controlled trials of at least 12 months in duration. Data from the three-year analysis of the MORE study confirms additional benefits with Evista therapy. As observed earlier, women taking Evista were no more likely to have vaginal bleeding than those taking placebo. Vaginal bleeding is a side effect common to conventional hormone replacement therapies. In addition, Evista did not increase endometrial cancer risks. Estrogen therapy alone has been linked to an increased risk of endometrial cancer and postmenopausal women with a uterus must usually take a progestin drug along with the estrogen to reduce this risk. Evista does not require concurrent use of any progestin drug. Women taking Evista continued to realise significant reductions in total cholesterol (about eight percent), LDL (more than 12 percent) and fibrinogen (more than 12 percent). Evista had a neutral effect on triglycerides and HDL. By three years of treatment, Evista therapy supplemented with calcium and vitamin D reduced an osteoporotic woman's risk of a first spinal fracture by 55 percent and an osteoporotic woman's risk of second or subsequent spinal fractures by 30 percent compared with women receiving only placebo supplemented with calcium and vitamin D. Spinal fractures are the most common of all osteoporosis-related fractures and tend to strike women at a younger age than fractures of the hip, wrist and ankle. "This finding should send a strong message to women that mineral supplements alone may not be enough to protect your bones if you are at risk for osteoporosis after menopause," Jordan said. "Taken together, Evista data validate the potential of SERMs to prevent osteoporosis and reduce the likelihood of fractures, and at the same time, reduce the incidence of breast cancer," he added. Evista is currently indicated for the prevention of postmenopausal osteoporosis. Evista is the only selective estrogen receptor modulator (SERM) available in the U.S. to protect postmenopausal women against the rapid loss of bone that occurs after menopause and often leads to thinning bones, osteoporosis and fractures. Evista is approved for marketing in 36 countries world-wide. As with most therapies, Evista is associated with some side effects, the majority of which were reported as mild. A rare but serious side effect is blood clots in the veins, which occurred in clinical trials at a rate similar to that reported for current users of estrogen or hormone replacement therapy. The most-commonly reported side effects in clinical trials were hot flashes and leg cramps, although most women did not find these events serious enough to discontinue therapy. Evista is contraindicated in women who are or may become pregnant because preclinical data suggest Evista can cause fetal harm.

To: Bull-like who wrote (445)	12/11/1998 4:05:00 PM
From: Anthony Wong	Respond to of 642

Bull, it's looking better and better. <eom>

To: Bull-like who wrote (445)	12/14/1998 1:51:00 PM
From: Anthony Wong	Respond to of 642

Eli Lilly & Co. Reiterated 'Strong Buy' at SG Cowen Bloomberg News December 14, 1998, 10:30 a.m. ET Princeton, New Jersey, Dec. 14 (Bloomberg Data) -- Eli Lilly & Co. (LLY US) was reiterated ''strong buy'' by analyst Stephen Scala at SG Cowen. -- Andrew Bekoff in Princeton, New Jersey, (609)279-3652

To: Bull-like who wrote (445)	12/14/1998 5:28:00 PM
From: Anthony Wong	Read Replies (2) \| Respond to of 642

NEWS! - Lilly gets FDA OK to expand Evista labeling Monday December 14, 4:13 pm Eastern Time INDIANAPOLIS, Dec 14 (Reuters) - Pharmaceutical company Eli Lilly and Co. said Monday it has been granted government approval to include on the label of its osteoporosis drug, Evista, that there is a lower incidence of breast cancer in post-menopausal women taking the drug. Evista was launched in the United States last January for the prevention in post-menopausal women of osteoporosis, a bone brittling disease. It is also approved for use in about 30 countries. Lilly said the U.S. Food and Drug Administration just approved the inclusion of expanded breast safety information into the physician product label. Lilly cautioned, however, that the effectiveness of Evista in reducing the risk of breast cancer has not yet been established over the longer term. ''We want to stress that this expanded label information is not a new indication, but rather validates the safety of Evista on breast tissue,'' the company said in a statement. In studies reported late last week, researchers said Evista cut the cancer rate in half among women who had taken the drug over three years. Lilly had tested Evista, known generically as raloxifene, on more than 10,000 women. biz.yahoo.com